Palo Alto Networks' (PANW) potential acquisition of CyberArk (CYBR) would complement Palo Alto's existing and bolster its ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the ...

Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious ad ...

An EU pharma lobby has criticized the Trump administration’s plans to impose 15% tariffs on pharmaceutical imports amid uncertainty over how the newly announced U.S.-EU trade deal targets the product ...

Haverhill contributed €14 million in net sales and €3 million in Core EBITDA in H1 2025 consolidated results, compared to €25 million in net sales and €9 million in Core EBITDA in H1 2024, and €35 ...

CyberArk Software ( NASDAQ: CYBR) soared 13% on a report that Palo Alto Networks ( NASDAQ: PANW) is in discussions to ...

A new real-world analysis from UK drugmaker Indivior (Nasdaq: INDV) suggests that patients with opioid use disorder (OUD) ...

Sarepta Therapeutics (Nasdaq: SRPT) has been cleared by the American medicines regulator to resume shipments of its gene ...

The US Food & Drug Administration (FDA) has approved Danish biotech Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd; ...

US biotech PTC Therapeutics’ shares trading up 4.8% to $46.48 in after-hours activity yesterday, as it announced that the US ...

Dr. Mates said: "Medincell is entering a new era and I’m excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innova ...

Sequential Acceleration in Like-for-like Growth 1 Further Operating Margin Expansion Sales: 22.47 billion euros,  +3.0% like-for-like 2(+3.2% adjusted 1 ), +1.6% reported.Adjusted for the phasing ...